Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • How big is the problem?
    • How we drive change
    • Our story
  • Featured insights
    • The latest at the Foundation
    • The latest at the Foundation
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • Become a catalyst
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
  • Achievements so far
    • The Foundation's impact
    • The Foundation's impact
  • News
  • Our team
  • Our impact
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us
Photo of: Emily Bleimund
Member of the 2022 Expert Review Committee for the Access to Medicine Index

Emily Bleimund

Emily Bleimund is a member of the 2022 Expert Review Committee for the Access to Medicine Index.

Emily is Director of Trade and Health in the U.S. Department of Health and Human Services (HHS) Office of Global Affairs. In this role, she represents the United States in multilateral health forums, develops HHS positions on trade-related issues, and represents HHS in international trade negotiations and in the U.S. government interagency trade policy process. Her principal topics of focus include access to medicines, intellectual property rights, health products regulation and pricing, nutrition policy and tobacco control. 

Prior to her current position, Emily worked at the FDA’s Center for Tobacco Products where she served as International Policy Counsel in the Office of Policy. In that role, Emily was the Center’s main point of contact for international issues, including the World Trade Organization dispute regarding the U.S. ban on clove cigarettes and the negotiations for the Trans-Pacific Partnership (TPP). Early in her career, Emily also worked for the American Cancer Society, where she focused on international tobacco control issues.

The Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Copyright 2004 - 2022 Access to Medicine Foundation - All Rights Reserved